No Carolina / NY / Florida
Ph: 561.316.3330

No Carolina | NY | Florida

NextVein Announces Affordable, High-Performance, Handheld Vein Visualization System

Editor: What To Know

  • This augmented reality system uses advanced camera and multicolor projection technology to project the vein pattern on the patient's skin, providing the clinician a roadmap to the patient's unique vasculature.
  • Excellent product at an affordable price is the right combination and will enable our customers to deliver a higher level of care and achieve a higher level of success.
  • The NextVein system is designed from the ground up to be a simple to use, cost-effective solution for successful venous access and vein avoidance.

NextVein LLC company today announced a breakthrough product that makes vein visualization affordable for every clinician. The NextVein system is designed from the ground up to be a simple to use, cost-effective solution for successful venous access and vein avoidance.

This augmented reality system uses advanced camera and multicolor projection technology to project the vein pattern on the patient’s skin, providing the clinician a roadmap to the patient’s unique vasculature. The LED projection system overcomes clinician and patient concerns about lasers.

Studies have shown that vein visualization improves important venous access metrics, including:

  • Improved first-time stick success rate,
  • Reduction in patient pain,
  • Fewer escalations,
  • Cost reduction.

NextVein is the first meaningful alternative to expensive vein visualization systems. It offers the core features expected from hand-held vein visualization and adds advanced features like multicolor projection. As a hand-held device, the clinician can quickly assess the patient to identify veins. It converts to hands-free with the NextVein wheeled stand, freeing both hands for the procedure. This state-of-the-art stand provides a reliable, long-reach solution for procedures and doubles as storage while re-charging.

Vein visualization is used:

  • To start IVs by nurses in hospitals and outpatient settings
  • To draw blood by phlebotomists
  • By Dentists, Dental Surgeons, and Dental Anesthesiologists for IV sedation
  • For IV contrast in Imaging Centers
  • For Aesthetic Injectables to avoid veins and visible bruising

NextVein is partnering with Medtech/Medcare (MTMC), the recognized leader in national sales solutions. Jack Moran, MTMC’s managing partner, said, “Our 125 sales executives are trusted partners to providers across the healthcare spectrum. We’re excited to bring this new high-performance, hand-held vein visualization system to our customers. Excellent product at an affordable price is the right combination and will enable our customers to deliver a higher level of care and achieve a higher level of success.”

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Recent News

CV Societies Propel Plans Forward for a New Board of Cardiovascular Medicine

“The open comment period is the time for cardiovascular physicians, allies in other medical specialties, patients, and others to make their voices heard on why an independent CV Board is the best path for cardiologists to stay up-to-date on best practices and evidence-based care, ensuring patients receive the best possible care,” said Jeffrey Kuvin, MD, president of the proposed Board’s new Board of Directors. “The field of cardiovascular medicine has evolved dramatically over the past few decades; now is the right time to develop an independent cardiovascular Board.”

Hyundai Bioscience Announces Clinical Development Plan for Niclosamide-based Metabolic Anticancer Drug Targeting P53 Mutation Cancer

Sang-ki Oh, CEO of Hyundai Bioscience, stated, "Niclosamide-based metabolic anticancer drug candidate will be the first P53-targeting anticancer treatment that selectively kills p53 mutated cancer cells," and added, "Through our subsidiary ADM Korea, we plan to conduct clinical trials targeting cancer patients with intractable cancer caused by p53 mutations, which will be the first step of clinical development on niclosamide-based anticancer agent pipeline."

Sedana Medical Completes Patient Recruitment for INSPiRE-ICU 1 Clinical Trial in the US

Peter Sackey further elaborated: "Once the 30-day follow-up of all patients is complete, we will enter into an intense phase of final monitoring, data cleaning and transfer to our statistician team for analysis. In parallel, the long-term outcomes at 3 and 6 months will be collected centrally by the Critical Illness, Brain Dysfunction, and Survivorship team at Vanderbilt Medical Center. With this parallel approach, we expect topline results in the autumn of this year and a swift regulatory submission in Q1, 2025".

Health / Lifestyle

Articles of Interest

Stay Connected

spot_img

About Medical Device News Magazine

About Medical Device News Magazine. A digital publication founded in 2008 located in the United States. The publication is one of the industry’s leading sources of medical device and biotech industry updates. Medical Device News Magazine is easily accessible 24/7/365 and is a fast 1, 2, 3 easy read! Our purpose is...

By using this website you agree to accept Medical Device News Magazine Privacy Policy